[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100566743":3},{"organization":4,"armGroups":7,"interventions":22,"overallOfficials":29,"centralContacts":34,"locations":42,"responsibleParty":73,"collaborators":75,"id":78,"slug":79,"hasResults":80,"nctId":81,"briefTitle":82,"officialTitle":83,"acronym":84,"eligibilityCriteria":85,"healthyVolunteers":80,"sex":86,"minAge":87,"maxAge":28,"enrollmentInfo":88,"targetDuration":28,"studyType":91,"phases":92,"briefSummary":94,"conditions":95,"keywords":28,"overallStatus":45,"whyStopped":28,"lastUpdateSubmitDate":99,"lastUpdatePostDateStruct":100,"startDateStruct":103,"completionDateStruct":105,"leadSponsor":107,"locationsCount":108},{"fullName":5,"class":6},"King's College London","OTHER",[8,14,18],{"label":9,"type":10,"description":11,"interventionNames":12},"Head and neck squamous cell carcinoma","EXPERIMENTAL","1\\) HNSCC i) Inoperable\u002Fincurable or recurrent\u002Fmetastatic HNSCC with no previous radiotherapy treatment ii) Inoperable\u002Fincurable or recurrent\u002Fmetastatic HNSCC with previous radiotherapy treatment (re-irradiation)",[13],"Device: Superficial hyperthermia",{"label":15,"type":10,"description":16,"interventionNames":17},"Cutaneous squamous cell carcinoma","2\\) cSCC i) Inoperable\u002Fincurable or recurrent\u002Fmetastatic cSCC with no previous radiotherapy treatment ii) Inoperable\u002Fincurable or recurrent\u002Fmetastatic cSCC with previous radiotherapy treatment (re-irradiation)",[13],{"label":19,"type":10,"description":20,"interventionNames":21},"Locally recurrent breast cancer","3\\) LRBC locally recurrent breast cancer with previous radiotherapy treatment (re-irradiation)",[13],[23],{"type":24,"name":25,"description":26,"armGroupLabels":27,"otherNames":28},"DEVICE","Superficial hyperthermia","Superficial hypothermia will be delivered using a CE-marked water-filtered infrared A (wIRA) machine (hydrosun® TWH1500)",[15,9,19],null,[30],{"name":31,"affiliation":32,"role":33},"Anthony Kong","Clinical reader and honorary NHS consultant in clinical oncology","PRINCIPAL_INVESTIGATOR",[35,39],{"name":31,"role":36,"phone":37,"phoneExt":28,"email":38},"CONTACT","44+2078486004","Anthony.Kong@kcl.ac.uk",{"name":40,"role":36,"phone":37,"phoneExt":28,"email":41},"Taylor McKenzie","taylor.mckenzie@kcl.ac.uk",[43,60],{"facility":44,"status":45,"city":46,"state":28,"zip":47,"country":48,"countryCode":49,"cosmosGeoPoint":50,"geoPoint":55,"contacts":56},"Guy's and St. Thomas NHS Foundation Trust","RECRUITING","London","SE1 9RT","United Kingdom","UK",{"type":51,"coordinates":52},"Point",[53,54],-0.12574,51.50853,{"lat":54,"lon":53},[57],{"name":31,"role":36,"phone":58,"phoneExt":28,"email":59},"44 + 207-848-8302","Anthony.kong@kcl.ac.uk",{"facility":61,"status":45,"city":46,"state":28,"zip":28,"country":48,"countryCode":49,"cosmosGeoPoint":62,"geoPoint":64,"contacts":65},"Guy's Cancer Centre",{"type":51,"coordinates":63},[53,54],{"lat":54,"lon":53},[66,70],{"name":67,"role":36,"phone":68,"phoneExt":28,"email":69},"Anthony Kong, MBBS PhD","+44 2078488302","anthony.kong@gstt.nhs.uk",{"name":71,"role":36,"phone":68,"phoneExt":28,"email":72},"Christiana Cattaneo, PhD","K2261905@kcl.ac.uk",{"type":74,"investigatorFullName":28,"investigatorTitle":28,"investigatorAffiliation":28,"oldNameTitle":28,"oldOrganization":28},"SPONSOR",[76],{"name":77,"class":6},"Guy's and St Thomas' NHS Foundation Trust","100566743","thermotherapy-in-addition-to-soc-palliative-radiotherapy-100566743",false,"NCT06659146","Thermotherapy in Addition to SOC Palliative Radiotherapy","Prospective Study to Assess the Real-world Implementation of Thermotherapy Using wIRA (Water-filtered Infrared A Superficial Hyperthermia) in Addition to Standard of Care (SOC) Palliative Radiotherapy (RT)","ThermoRad wIRA","Inclusion Criteria:\n\n1. Patient with histologically confirmed incurable or inoperable cancers with disease \\[at least one superficial lesion(s) or lymph node(s)\\] suitable for hydrosun® TWH1500 treatment\n2. Patient undergoing standard of care palliative radiotherapy (suitable with the pre-specified dose and fractionation in the protocol\n3. Aged ≥18 years old\n4. Eastern Cooperative Oncology Group (ECOG) performance status 0 to 1\n5. Patient with capacity to consent\n\nExclusion Criteria:\n\n1. No superficial tumour lesion or lymph node that is suitable for hydrosun® TWH1500 treatment.\n2. Patients are not suitable for one of the pre-specified palliative radiotherapy dose and fractionation\n3. Has known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the study.","ALL","18 Years",{"count":89,"type":90},60,"ESTIMATED","INTERVENTIONAL",[93],"NA","This study aims to investigate the efficacy and safety profile of superficial hyperthermia (wIRA) in addition to standard of care (SOC) palliative radiotherapy in patients with inoperable\u002Fincurable locally advanced or recurrent\u002Fmetastatic HNSCC or cutaneous SCC superficial tumours not suitable for radical treatment.\n\nThe investigators will assess the best objective response rate (ORR) of patients with Inoperable\u002Fincurable or recurrent\u002Fmetastatic HNSCC or cSCC with superficial lesion(s) treated with the combination of superficial hyperthermia (wIRA) and palliative radiotherapy.",[96,97,98],"Head and Neck Squamous Cell Carcinoma","Cutaneous Squamous Cell Carcinoma","Breast Cancer Recurrent","2025-12-15",{"date":101,"type":102},"2025-12-22","ACTUAL",{"date":104,"type":102},"2024-10-14",{"date":106,"type":90},"2028-03-01",{"name":5,"class":6},2]